Fulgent Genetics/$FLGT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fulgent Genetics
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Ticker
$FLGT
Sector
Primary listing
Industry
Health Care Providers and Services
Headquarters
Employees
1,313
Website
Fulgent Genetics Metrics
BasicAdvanced
$523M
-
-$1.34
1.01
-
Price and volume
Market cap
$523M
Beta
1.01
52-week high
$25.11
52-week low
$14.57
Average daily volume
254K
Financial strength
Current ratio
6.323
Quick ratio
6.08
Long term debt to equity
0.545
Total debt to equity
0.737
Interest coverage (TTM)
-5,136.79%
Profitability
EBITDA (TTM)
-47.731
Gross margin (TTM)
38.80%
Net profit margin (TTM)
-13.94%
Operating margin (TTM)
-24.59%
Effective tax rate (TTM)
15.42%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-3.69%
Return on equity (TTM)
-3.72%
Valuation
Price to revenue (TTM)
1.792
Price to book
0.47
Price to tangible book (TTM)
0.54
Price to free cash flow (TTM)
-16.575
Free cash flow yield (TTM)
-6.03%
Free cash flow per share (TTM)
-1.036
Growth
Revenue change (TTM)
1.71%
Earnings per share change (TTM)
-75.96%
3-year revenue growth (CAGR)
-32.56%
3-year earnings per share growth (CAGR)
-55.15%
What the Analysts think about Fulgent Genetics
Analyst ratings (Buy, Hold, Sell) for Fulgent Genetics stock.
Bulls say / Bears say
Fulgent Genetics is expanding its therapeutic development business, focusing on innovative cancer treatments using a nanoencapsulation and targeted therapy platform, which could open new revenue streams. (stocktitan.net)
The company's Picture Genetics platform offers advanced genetic testing solutions, positioning Fulgent as a leader in personalized medicine. (stocktitan.net)
Analysts have set a one-year price target of $22.67 for Fulgent Genetics, indicating potential upside from its current trading price. (simplywall.st)
Fulgent Genetics reported a net loss of $41.87 million over the latest four quarters, raising concerns about its profitability. (marketsmojo.com)
The company's revenue heavily depends on COVID-19 testing, which may decline post-pandemic, potentially impacting future earnings. (danelfin.com)
Fulgent faces competitive pressure from established players in the genomics industry, which could affect its market share and pricing power. (danelfin.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Fulgent Genetics Financial Performance
Revenues and expenses
Fulgent Genetics Earnings Performance
Company profitability
Fulgent Genetics News
AllArticlesVideos
Fulgent Reports Second Quarter 2025 Financial Results
Business Wire·4 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Accesswire·2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulgent Genetics stock?
Fulgent Genetics (FLGT) has a market cap of $523M as of August 01, 2025.
What is the P/E ratio for Fulgent Genetics stock?
The price to earnings (P/E) ratio for Fulgent Genetics (FLGT) stock is 0 as of August 01, 2025.
Does Fulgent Genetics stock pay dividends?
No, Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Fulgent Genetics dividend payment date?
Fulgent Genetics (FLGT) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulgent Genetics?
Fulgent Genetics (FLGT) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.